Training Course Oncology Drug Development in Practice (ODDP) 2017

Training Course Oncology Drug Development in Practice (ODDP) is organized by Congress by design and would be held during Nov 22 - 24, 2017 at Mercure Hotel Amsterdam City, Amsterdam, Noord Holland, Netherlands.

Target audience :

This program is of particular interest to (junior) physicians at academic hospitals and other clinical centers involved in clinical trials of new cancer therapies. ODDP 2017 is a 3-day educational program that serves several target audiences:

• Anyone looking for a solid introduction into the essentials of oncology will benefit from participating in part A;
• Drug development professionals in industry and academia wishing to acquire or expand knowledge of oncology drug development will benefit from participating in parts A and B combined or part B only, depending on their starting level of oncology knowledge.

Oncology Drug Development in Practice (ODDP) is an educational program designed for professionals in academia and industry who wish to acquire or expand their knowledge of drug development in oncology.

Education offered

Part A offers education on tumor biology, pathology, and various domains of cancer patient management in sessions dedicated to:
Part B offers education on anticancer drug development, with a focus on the situation in Europe, and a number of associated areas in sessions dedicated to:

(Speakers): Education will be presented by experts from leading academic research institutes and oncology-orientated drug companies, all having ample expertise and hands-on experience in cancer research, clinical oncology, and/or anticancer drug development.

(Attendees): Drug development professionals in industry and academia (*) wishing to acquire or expand knowledge of oncology drug development will benefit from participating in parts A and B combined or part B only, depending on their starting level of oncology knowledge.

Topics: Cancer and cancer therapeutics, Carcinogenesis & tumor cell biology, Oncopathology: Diagnosing cancer, Essentials of medical oncology, Essentials of hemato-oncology, Essentials of cancer immunotherapy, Drug discovery and preclinical drug testing, Preclinical toxicology of anticancer agents, Phase 1 clinical studies with single agents, Phase 1 clinical studies with combinations of agents, Full clinical development of cancer therapeutics, Post-registration drug development in oncology, Biomarkers in oncology drug development, Development of companion diagnostics, for cancer therapeutics, The regulatory environment for anticancer, drug development, Biostatistical considerations in oncology, clinical trials

Why participate in ODDP 2017?

• Exclusively focused on oncology
• Impressive 13-year track record
• High participaant satisfaction over the years
• Particularly useful for those entering oncology drug development
• No upfront oncology knowledge required for successful participation
• Covers the complete cancer drug development process
• Provides stand-alone introduction into oncology for a broad audience

Additional details will be posted as soon as they are available.